Top Bipolar Disorder Companies

Skyquest Technology's expert advisors have carried out comprehensive research and identified these companies as industry leaders in the Bipolar Disorder Market. This Analysis is based on comprehensive primary and secondary research on the corporate strategies, financial and operational performance, product portfolio, market share and brand analysis of all the leading Bipolar Disorder industry players.

Bipolar Disorder Market Competitive Landscape

Global bipolar disorder market is relatively fragmented, with a high level of competition. The prominent players operating in the market are constantly adopting various growth strategies to stay afloat in the market. Product launches, innovations, mergers, and acquisitions, collaborations and partnerships, and intensive R&D are some of the growth strategies that are adopted by these key players to thrive in the competitive market. The key market players are also constantly focused on R&D to supply industries with the most efficient and cost-effective solutions.

Top Players in the Global Bipolar Disorder Market

  • Eli Lilly and Company (USA) 
  • GlaxoSmithKline plc (UK) 
  • Pfizer Inc. (USA) 
  • AstraZeneca plc (UK) 
  • Otsuka Holdings Co., Ltd. (Japan) 
  • H. Lundbeck A/S (Denmark) 
  • Teva Pharmaceutical Industries Ltd. (Israel) 
  • Takeda Pharmaceutical Company Limited (Japan) 
  • AbbVie Inc. (USA) 
  • Novartis International AG (Switzerland) 
  • Merck & Co., Inc. (USA) 
  • Bristol Myers Squibb Company (USA) 
  • Alkermes plc (Ireland) 
  • Mylan N.V. (USA) 
  • Neurocrine Biosciences, Inc. (USA) 
  • Vanda Pharmaceuticals Inc. (USA) 
  • Sunovion Pharmaceuticals Inc. (USA) 
  • Intra-Cellular Therapies, Inc. (USA) 
  • Acadia Pharmaceuticals Inc. (USA) 
  • Reviva Pharmaceuticals Holdings, Inc. (USA)

Bipolar Disorder Market

REPORT OVERVIEW BUY NOW

REQUEST FOR SAMPLE

Want to customize this report? REQUEST FREE CUSTOMIZATION

FAQs

Global Bipolar Disorder Market size was valued at USD 5.36 billion in 2023 and is poised to grow from USD 5.49 billion in 2024 to USD 6.64 billion by 2032, growing at a CAGR of 2.4% during the forecast period (2025-2032).

Global bipolar disorder market is relatively fragmented, with a high level of competition. The prominent players operating in the market are constantly adopting various growth strategies to stay afloat in the market. Product launches, innovations, mergers, and acquisitions, collaborations and partnerships, and intensive R&D are some of the growth strategies that are adopted by these key players to thrive in the competitive market. The key market players are also constantly focused on R&D to supply industries with the most efficient and cost-effective solutions. 'Eli Lilly and Company (USA) ', 'GlaxoSmithKline plc (UK) ', 'Pfizer Inc. (USA) ', 'AstraZeneca plc (UK) ', 'Otsuka Holdings Co., Ltd. (Japan) ', 'H. Lundbeck A/S (Denmark) ', 'Teva Pharmaceutical Industries Ltd. (Israel) ', 'Takeda Pharmaceutical Company Limited (Japan) ', 'AbbVie Inc. (USA) ', 'Novartis International AG (Switzerland) ', 'Merck & Co., Inc. (USA) ', 'Bristol Myers Squibb Company (USA) ', 'Alkermes plc (Ireland) ', 'Mylan N.V. (USA) ', 'Neurocrine Biosciences, Inc. (USA) ', 'Vanda Pharmaceuticals Inc. (USA) ', 'Sunovion Pharmaceuticals Inc. (USA) ', 'Intra-Cellular Therapies, Inc. (USA) ', 'Acadia Pharmaceuticals Inc. (USA) ', 'Reviva Pharmaceuticals Holdings, Inc. (USA)'

The market for treating bipolar illness is anticipated to rise over the forecast period as key players concentrate on expanding their product portfolio through an increase in the launches and approvals of new pharmaceuticals for the condition. For instance, in May 2019, the U.S. Food and Drug Administration (FDA) approved Allergan plc and Gedeon Richter plc's supplemental new drug application (sNDA) for VRAYLAR (cariprazine), an oral, once-daily atypical antipsychotic drug for the expanded use and treatment of depressive episodes related to bipolar I disorder (bipolar depression) in adults.

Rising cases of mental illness: As non-ambiguous cases of illness have been increasingly prevalent in the population, bipolar disorder in children and adolescents has become a common diagnosis.

Geographically, North America is anticipated to dominate the global bipolar disorder market due to the region's high levels of stress and widespread substance misuse problems. Various government programmes and efforts meant to increase awareness fuel the rise of the market in Europe and North America. The North America region demonstrated its dominance by accounting for over 50% of the global market for bipolar disorder in 2019 and anticipated for the forecast period. The market demand is significantly rising due to the Y-O-Y increase in the prevalence of bipolar disorder in this region. The prevalence of bipolar disorder is rising in the North America, which is driving the regional market. A sizeable portion of the population in this region has high levels of stress and sleep problems.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here right-arrow
logo-images

Related Reports

Mental Health Market
Buy Now GET FREE SAMPLE
Lithium Market
Buy Now GET FREE SAMPLE
Sleep Disorder Market
Buy Now GET FREE SAMPLE
Mental Health Software Market
Buy Now GET FREE SAMPLE
FMD Disease Market
Buy Now GET FREE SAMPLE
Bipolar Junction Transistors (BJTs) Market
Buy Now GET FREE SAMPLE
Schizophrenia Drugs Market
Buy Now GET FREE SAMPLE
Behavioral Mental Health Software Market
Buy Now GET FREE SAMPLE

Feedback From Our Clients

Global Bipolar Disorder Market
Bipolar Disorder Market

Report ID: SQMIG35I2095

[email protected]
USA +1 351-333-4748

BUY NOW GET FREE SAMPLE